The introduction of new agents immunomodulatory drugs (IMiDs) and proteasome inhibitors has brought a major shift in therapeutic paradigm in the treatment of newly diagnosed and refractory ...

Despite impressive therapeutic progresses in the battle against infections, microorganisms are still a threat to mankind. With hundreds of antibacterial molecules, major concerns remain about the ...

Multiple sclerosis (MS) is an autoimmune disease caused by activated autoimmune T lymphocytes in patients resulting in inflammatory demyelination in the central nervous system. A specific therapy ...

Nuvig Therapeutics Announces $161 Million Series B Financing and Progression to Phase 2 Development with Novel, ...

Data from the ongoing Phase 2 of EO4010 demonstrate tumor target specific immune responses and objective tumor responses, including in liver ...

A study provides insights into the diversity of cancer-associated fibroblasts in white and black skin cancer and describes their different immunomodulatory roles in the tumor environment.

CVC Capital Partners has completed the previously announced acquisition of Therakos from Mallinckrodt. St Louis, Missouri-based Therakos is a provider of extracorporeal photopheresis (ECP) delivery ...

Ciltacabtagene autoleucel (cilta-cel; Carvykti) is now approved as a second-line therapy for patients who are refractory to lenalidomide (Revlimid), an immunomodulatory agent, and whose prior line ...